loading
전일 마감가:
$21.24
열려 있는:
$21.38
하루 거래량:
898.53K
Relative Volume:
0.45
시가총액:
$3.73B
수익:
$890.53M
순이익/손실:
$30.57M
주가수익비율:
116.39
EPS:
0.18
순현금흐름:
$80.53M
1주 성능:
-5.67%
1개월 성능:
-4.69%
6개월 성능:
+13.80%
1년 성능:
+34.38%
1일 변동 폭
Value
$20.84
$21.41
1주일 범위
Value
$20.84
$22.56
52주 변동 폭
Value
$13.40
$25.23

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
명칭
Acadia Pharmaceuticals Inc
Name
전화
858-558-2871
Name
주소
12830 EL CAMINO REAL, SAN DIEGO
Name
직원
654
Name
트위터
@acadiapharma
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
ACAD's Discussions on Twitter

ACAD을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ACAD
Acadia Pharmaceuticals Inc
20.95 3.73B 890.53M 30.57M 80.53M 0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-21 업그레이드 Deutsche Bank Hold → Buy
2025-02-11 개시 Deutsche Bank Hold
2025-01-03 다운그레이드 Guggenheim Buy → Neutral
2024-10-10 재개 Raymond James Mkt Perform
2024-08-07 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2024-06-27 개시 BMO Capital Markets Outperform
2024-03-12 다운그레이드 Mizuho Buy → Neutral
2024-03-12 재확인 Needham Buy
2024-01-30 개시 Robert W. Baird Outperform
2024-01-24 업그레이드 Needham Hold → Buy
2023-12-19 업그레이드 Morgan Stanley Equal-Weight → Overweight
2023-12-14 다운그레이드 Deutsche Bank Buy → Hold
2023-12-13 개시 Citigroup Buy
2023-12-12 개시 Deutsche Bank Buy
2023-11-06 업그레이드 Mizuho Neutral → Buy
2023-10-17 개시 UBS Buy
2023-10-10 업그레이드 JP Morgan Neutral → Overweight
2023-01-03 업그레이드 Guggenheim Neutral → Buy
2022-11-04 다운그레이드 Goldman Neutral → Sell
2022-11-01 개시 Loop Capital Hold
2022-08-08 다운그레이드 Citigroup Buy → Neutral
2022-08-05 다운그레이드 Citigroup Buy → Neutral
2022-06-21 다운그레이드 Jefferies Buy → Underperform
2022-06-16 업그레이드 Jefferies Hold → Buy
2022-03-16 업그레이드 Canaccord Genuity Hold → Buy
2022-02-09 업그레이드 H.C. Wainwright Neutral → Buy
2022-01-05 업그레이드 Citigroup Neutral → Buy
2021-12-21 다운그레이드 Guggenheim Buy → Neutral
2021-11-01 업그레이드 Guggenheim Neutral → Buy
2021-10-14 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-09-23 재개 Needham Hold
2021-06-10 개시 Berenberg Hold
2021-04-07 다운그레이드 H.C. Wainwright Buy → Neutral
2021-04-06 다운그레이드 Canaccord Genuity Buy → Hold
2021-04-06 다운그레이드 Goldman Buy → Neutral
2021-04-06 다운그레이드 Jefferies Buy → Hold
2021-04-06 다운그레이드 Mizuho Buy → Neutral
2021-04-05 다운그레이드 Raymond James Outperform → Mkt Perform
2021-03-10 다운그레이드 BofA Securities Buy → Neutral
2021-03-09 다운그레이드 Citigroup Buy → Neutral
2021-03-09 다운그레이드 Guggenheim Buy → Neutral
2021-03-09 재확인 H.C. Wainwright Buy
2021-03-09 다운그레이드 Raymond James Strong Buy → Outperform
2021-03-09 다운그레이드 Stifel Buy → Hold
2020-12-16 개시 Mizuho Buy
2020-11-16 업그레이드 Raymond James Outperform → Strong Buy
2020-08-25 개시 Raymond James Outperform
2020-08-20 개시 Morgan Stanley Overweight
2020-07-07 업그레이드 Stifel Hold → Buy
2020-04-16 개시 Jefferies Buy
2020-03-31 업그레이드 Goldman Neutral → Buy
2020-03-06 개시 Citigroup Buy
2019-12-16 개시 Guggenheim Buy
2019-10-24 개시 Oppenheimer Perform
2019-10-01 개시 RBC Capital Mkts Outperform
2019-09-13 업그레이드 SVB Leerink Mkt Perform → Outperform
2019-09-10 업그레이드 Canaccord Genuity Hold → Buy
2019-07-23 재확인 Needham Buy
2018-12-10 개시 Canaccord Genuity Hold
2018-09-21 업그레이드 Piper Jaffray Neutral → Overweight
2018-08-09 재확인 Stifel Hold
2018-08-07 개시 Stifel Hold
2018-08-06 다운그레이드 Piper Jaffray Overweight → Neutral
2017-10-06 재개 Goldman Neutral
모두보기

Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스

pulisher
Jun 18, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three years - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Bavarian Nordic sells priority review voucher to US healthcare system USD 160m - medwatch.com

Jun 18, 2025
pulisher
Jun 17, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ACAD Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Neuroscience Leader Acadia Pharmaceuticals Expands Team with 41 New Hires, Awards $4.1M in Stock Options - Stock Titan

Jun 17, 2025
pulisher
Jun 17, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 17, 2025
pulisher
Jun 14, 2025

Acadia wins patent appeal for key drug composition By Investing.com - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech

Jun 13, 2025
pulisher
Jun 12, 2025

US appeals court confirms patent validity of Acadia's Parkinson's drug - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA

Jun 12, 2025
pulisher
Jun 11, 2025

Acadia Pharmaceuticals (ACAD) Secures Patent Win to Maintain Nup - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication - Insider Monkey

Jun 11, 2025
pulisher
Jun 10, 2025

Acadia wins patent appeal for key drug composition - Investing.com Australia

Jun 10, 2025
pulisher
Jun 10, 2025

Acadia gets court approval related to Nuplazid patent - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies - Life Sciences Intellectual Property Review

Jun 10, 2025
pulisher
Jun 10, 2025

ACAD Patent Victory Secures Nuplazid Exclusivity Till 2030 | ACA - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

US appeals court upholds Acadia’s patent for Parkinson’s drug in MSN Labs case - BusinessLine

Jun 10, 2025
pulisher
Jun 09, 2025

Acadia secures NUPLAZID patent protection through 2030 By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Win On Parkinson's Drug Patent Upheld By Fed. Circ. - Law360

Jun 09, 2025
pulisher
Jun 09, 2025

Federal Court Upholds Acadia Pharmaceuticals (ACAD) Patent Victo - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Pharmaceuticals (ACAD) Secures Patent Victory - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Pharmaceuticals Again Prevails in Appeal Upholding Patent for Parkinson's Drug - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : ACADIA Pharmaceuticals Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Drug - U.S. News & World Report

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia gets court approval related to Nuplazid patent (ACAD) - Seeking Alpha

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Pharmaceuticals says Appeals Court confirms validity of NUPLAZID patent - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia secures NUPLAZID patent protection through 2030 - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

U.S. Court Of Appeals For The Federal Circuit Affirms Prior Delaware District Court Rulings In Favor Of Acadia In Nuplazid® (Pimavanserin) Composition Of Matter Patent - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Acadia Pharma (ACAD) announces affirmation from U.S. Court of Appeals in favor of Acadia in NUPLAZID patent - StreetInsider

Jun 09, 2025
pulisher
Jun 09, 2025

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent - Yahoo

Jun 09, 2025
pulisher
Jun 06, 2025

JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory - Benzinga

Jun 06, 2025
pulisher
Jun 06, 2025

JPMorgan Raises Acadia Pharmaceuticals (ACAD) Price Target to $3 - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

JPMorgan raises Acadia Pharmaceuticals stock price target to $30 - Investing.com Australia

Jun 06, 2025
pulisher
Jun 06, 2025

ACADIA Pharmaceuticals (ACAD) Receives Price Target Boost from J - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

ACADIA Pharmaceuticals (ACAD) Receives Price Target Boost from JP Morgan | ACAD Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

JPMorgan raises Acadia Pharmaceuticals stock price target to $30 By Investing.com - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

Acadia Pharmaceuticals price target raised to $30 from $26 at JPMorgan - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

JPMorgan Raises Acadia Pharmaceuticals (ACAD) Price Target to $30 Following Patent Win | ACAD Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 05, 2025

Insider Sell: Laura Brege Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

The Analyst Verdict: ACADIA Pharmaceuticals In The Eyes Of 11 Experts - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

ACADIA Pharmaceuticals (ACAD) Price Target Raised by B of A Secu - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

ACADIA Pharmaceuticals (ACAD) Price Target Raised by B of A Securities | ACAD Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025 - BioSpace

Jun 05, 2025
pulisher
Jun 05, 2025

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025 | ACAD Stock News - GuruFocus

Jun 05, 2025

Acadia Pharmaceuticals Inc (ACAD) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.39
price down icon 0.34%
$36.24
price down icon 0.27%
$23.15
price up icon 7.69%
$96.83
price down icon 0.40%
$108.13
price up icon 0.15%
biotechnology ONC
$247.47
price up icon 1.13%
자본화:     |  볼륨(24시간):